Search results for "vitamin K"

showing 10 items of 108 documents

Age-dependent differences in the effect of phenprocoumon on the vitamin K1-epoxide cycle in rats

1980

Abstract The anticoagulant activity and the pharmacokinetics of phenprocoumon as well as the effect of phenprocoumon on the vitamin K1-epoxide cycle in younger (12 weeks) and older (36 weeks) male inbred Lewis rats has been examined in a study of the mechanism responsible for the increase in the responsiveness to oral anticoagulant drugs (OAD's) with increasing age. After a single i.v.-dose of phenprocoumon (0†355 mg kg−1 the anticoagulant effect obtained was greater in older than in younger rats. There were no differences between younger and older rats in the rate of elimination, volume of distribution and in the free fraction and free concentration values of phenprocoumon in plasma and li…

VitaminMetabolitePharmaceutical SciencePharmacologyReductasePhenprocoumonchemistry.chemical_compoundPharmacokineticsEthers CyclicmedicineAnimalsPharmacologyVolume of distributionchemistry.chemical_classificationDose-Response Relationship DrugChemistryAge Factors4-HydroxycoumarinsVitamin K 1RatsKineticsEnzymeLiverFree fractionPhenprocoumonEpoxy Compoundsmedicine.drugJournal of Pharmacy and Pharmacology
researchProduct

The Role of Vitamin Deficiency in Liver Disease: To Supplement or Not Supplement?

2021

Over the past few years, growing interest has been shown for the impact of dietary requirements and nutritional factors on chronic diseases. As a result, nutritional programs have been reinforced by public health policies. The precise role of micronutrients in chronic liver disease is currently receiving particular attention since abnormalities in vitamin levels are often detected. At present, treatment programs are focused on correcting vitamin deficiencies, which are frequently correlated to higher rates of comorbidities with poor outcomes. The literature reviewed here indicates that liver diseases are often related to vitamin disorders, due to both liver impairment and abnormal intake. M…

Vitaminmedicine.medical_specialtyPhysiologyReviewSpecific knowledgeChronic liver diseaseVitaminchemistry.chemical_compoundLiver diseaseVitamin deficiencymedicineMicronutrientAvitaminosiHumansVitamin E DeficiencyTX341-641Nutrition and DieteticsVitamin A DeficiencyNutrition. Foods and food supplybusiness.industryLiver DiseasesPublic healthMalnutritionNutritional Requirementschronic liver diseaseAvitaminosisvitamin supplementationVitamin D Deficiencyvitaminsmedicine.diseaseMicronutrientLiver TransplantationDietary RequirementschemistrymicronutrientsDietary SupplementsAscorbic Acid DeficiencyVitamin K DeficiencybusinessHumanFood ScienceNutrients
researchProduct

Hereditary combined deficiency of the vitamin K-dependent clotting factors

2010

Abstract Hereditary combined vitamin K-dependent clotting factors deficiency (VKCFD) is a rare congenital bleeding disorder resulting from variably decreased levels of coagulation factors II, VII, IX and X as well as natural anticoagulants protein C, protein S and protein Z. The spectrum of bleeding symptoms ranges from mild to severe with onset in the neonatal period in severe cases. The bleeding symptoms are often life-threatening, occur both spontaneously and in a surgical setting, and usually involve the skin and mucosae. A range of non-haemostatic symptoms are often present, including developmental and skeletal anomalies. VKCFD is an autosomal recessive disorder caused by mutations in …

Vitaminmedicine.medical_specialtyVitamin KCoagulation Factor Deficiencylcsh:MedicineReviewGastroenterologyProtein SProtein SSettore MED/15 - Malattie Del Sanguechemistry.chemical_compoundBlood Coagulation Disorders InheritedInternal medicineVitamin K deficiencymedicineHumansGenetics(clinical)Pharmacology (medical)VITAMIN K DEPENDENT CLOTTING FACTORS RARE INHERITED BLEEDING DISORDERSCongenital Bleeding DisorderGenetics (clinical)Medicine(all)Clotting factorbiologybusiness.industrylcsh:RVitamin K2WarfarinInfant NewbornGeneral MedicineBlood Proteinsmedicine.diseaseBlood Coagulation FactorsRecombinant ProteinschemistryCarbon-Carbon LigasesImmunologybiology.proteinVitamin K Deficiencybusinessmedicine.drugProtein C
researchProduct

Orālo antikoagulantu aprite SIA "Jēkabpils Vecpilsētas aptieka" laika periodā no 2017. līdz 2019. gadam

2020

Sirds išēmiskās slimības un insults ir viens no galvenajiem iemesliem mirstībai pasaulē. Šīs slimības pēdējos 15 gados ir bijušas galvenie nāves cēloņi visā pasaulē. Ir dažādas slimības, kad iesaka ārstēšanu ar antikoagulantiem. Biežākā no tām ir mirdzaritmija (MA) jeb priekškambaru (ātriju) fibrillācija (ĀF). Antikoagulantu lietošana dažādās vecuma grupās ir plaši izplatīta visā pasaulē. Eiropas ārstēšanas vadlīnijas mirdzaritmijas izraisīta insulta profilaksei neiesaka lietot antiagregantus, piemēram, aspirīnu, bet iesaka lietot antikoagulantus kā visefektīvākās zāles, jo tie var mazināt risku par divām trešdaļām vai pat vairāk. Bez antikoagulantu terapijas aptuveni 1 no 20 mirdzaritmijas…

anticoagulantsantikoagulantiVitamin K antagonistsK vitamīna antagonistiFarmācijaNOAC
researchProduct

Assessment of Dietary Intake of Vitamin K and Maximum Limits for Vitamin K in Food Supplements

2019

The Norwegian Scientific Committee for Food and Environment (Vitenskapskomiteen for mat og miljø, VKM) has, at the request of the Norwegian Food Safety Authority (Mattilsynet; NFSA), evaluated the intake of vitamin K in the diet. VKM has also assessed the consequences of establishing maximum limits for vitamin K in food supplements at 100, 200, 300, 600 or 800 µg/day. The former maximum limit for vitamin K of 200 µg/day in food supplements was repealed 30 May 2017.
 Vitamin K is a fat-soluble vitamin required for the carboxylation of glutamic acid residues in proteins that regulate blood coagulation and bone metabolism. The naturally occurring forms of vitamin K present in food and sup…

business.industryDietary intakeMedicineFood scienceVitamin kRisk assessmentbusinessEuropean Journal of Nutrition & Food Safety
researchProduct

Experimental evidence for proton motive force-dependent catalysis by the diheme-containing succinate:menaquinone oxidoreductase from the Gram-positiv…

2006

In Gram-positive bacteria and other prokaryotes containing succinate:menaquinone reductases, it has previously been shown that the succinate oxidase and succinate:menaquinone reductase activities are lost when the transmembrane electrochemical proton potential, Deltap, is abolished by the rupture of the bacteria or by the addition of a protonophore. It has been proposed that the endergonic reduction of menaquinone by succinate is driven by the electrochemical proton potential. Opposite sides of the cytoplasmic membrane were envisaged to be separately involved in the binding of protons upon the reduction of menaquinone and their release upon succinate oxidation, with the two reactions linked…

chemistry.chemical_classificationbiologyProtonophoreChemiosmosisSuccinic AcidProton-Motive ForceBacillusVitamin K 2HemeReductasebiology.organism_classificationBiochemistryRedoxCatalysisSuccinate DehydrogenaseEnzymeBiochemistrychemistryBacterial ProteinsFumaratesOxidoreductaseBacillus licheniformisOxidoreductasesOxidation-ReductionBacteriaBiochemistry
researchProduct

Functional investigation and applications of the acetylesterase activity of the Citrus sinensis (L.) Osbeck peel

2020

The hydrolysis of acetyl moieties on a set of commercially relevant substrates was performed by employing the whole tissue of Citrus sinensis (L.) Osbeck peel as an efficient biocatalyst in mild reaction conditions with high degree of regioselectivity. The reaction is done in aqueous media and the product is easily recovered. Optimal reaction conditions were deduced and two practical applications were investigated: the elaboration of acetylglicerols and the preparation of vitamin K1 precursor. Peel waste (flavedo and albedo) from orange juice manufacturing was successfully employed as a biocatalyst.

genetic structures010405 organic chemistryChemistryOrganic Chemistryfood and beveragesAcetylesterase activitySettore CHIM/06 - Chimica OrganicaPlant Scienceequipment and supplies01 natural sciencesBiochemistryenzymatic biocatalysi0104 chemical sciencesAnalytical Chemistry010404 medicinal & biomolecular chemistryHydrolysisFood sciencevitamin K1Citrus × sinensisacetate hydrolysiacetinCitrus sinensiNatural Product Research
researchProduct

Telemedicine-Based Specialized Care Improves the Outcome of Anticoagulated Individuals with Venous Thromboembolism-Results from the thrombEVAL Study.

2020

Venous thromboembolism (VTE) is a life-threatening disease with risk of recurrence. Oral anticoagulation (OAC) with vitamin K antagonists (VKA) is effective to prevent thromboembolic recurrence. We aimed to investigate the quality of OAC of VTE patients in regular medical care (RMC) compared to a telemedicine-based coagulation service (CS). The thrombEVAL study (NCT01809015) is a prospective, multi-center study to investigate OAC treatment (recruitment: January 2011&ndash

medicine.medical_specialtyANTITHROMBOTIC THERAPYPULMONARY-EMBOLISMvenous thromboembolismlcsh:Medicine030204 cardiovascular system & hematologyRate ratioWARFARINArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineORAL ANTICOAGULATION030212 general & internal medicineAdverse effectcoagulation serviceINR CONTROLNORMALIZED RATIO CONTROLPRACTICAL MANAGEMENTbusiness.industrySTROKE PREVENTIONlcsh:RHazard ratioWarfarinAtrial fibrillationGeneral Medicinemedicine.diseaseConfidence intervalMEDICAL-CAREPulmonary embolismvitamin K antagonistsATRIAL-FIBRILLATIONe-healthbusinessoral anticoagulation therapymedicine.drugJournal of clinical medicine
researchProduct

Genotype-driven pharmacokinetic simulations of warfarin levels in Puerto Ricans.

2020

Abstract Objectives The inter-individual variability of warfarin dosing has been linked to genetic polymorphisms. This study was aimed at performing genotype-driven pharmacokinetic (PK) simulations to predict warfarin levels in Puerto Ricans. Methods Analysis of each individual dataset was performed by one-compartmental modeling using WinNonlin®v6.4. The k e of warfarin given a cytochrome P450 2C9 (CYP2C9) genotype ranged from 0.0189 to 0.0075 h−1. K a and V d parameters were taken from literature. Data from 128 subjects were divided into two groups (i.e., wild-types and carriers) and statistical analyses of PK parameters were performed by unpaired t-tests. Results In the carrier group (n=6…

medicine.medical_specialtyGenotypeCmax030204 cardiovascular system & hematology030226 pharmacology & pharmacyGastroenterologyArticle03 medical and health sciences0302 clinical medicinePharmacokineticsVitamin K Epoxide ReductasesInternal medicineGenotypemedicineHumansPharmacology (medical)DosingGeneral Pharmacology Toxicology and PharmaceuticsCYP2C9GenotypingCytochrome P-450 CYP2C9business.industryWarfarinArea under the curveFarmàcia InvestigacióAnticoagulantsHispanic or LatinoAryl Hydrocarbon HydroxylasesWarfarinbusinessmedicine.drugDrug metabolism and personalized therapy
researchProduct

Long-term oral anticoagulation for atrial fibrillation in low and middle income countries.

2021

With increasing life-expectancy and changing demographics, non-valvular atrial fibrillation (AF) is currently the most common indication for long-term oral anticoagulation (OAC) in low and middle income countries (LMICs). Due to a decreasing trend in the prevalence of rheumatic heart disease (RHD), valve disease as a primary cause of AF now constitutes a small fraction of all people with AF. Moreover, emerging data also indicate that, patients with significant valve disease and AF may have a risk of stroke similar to, if not lower than, those with non-valvular AF. Previous trials of anticoagulation for AF excluded people from LMICs partly because valvular AF constituted a large proportion o…

medicine.medical_specialtyHeart diseaseRD1-811medicine.drug_classMEDLINEAdministration Oral030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineThromboembolismAtrial FibrillationOpinion PapermedicineDiseases of the circulatory (Cardiovascular) systemHumans030212 general & internal medicineMedical prescriptionIntensive care medicineStrokeDeveloping Countriesbusiness.industryvalvular heart diseaseAnticoagulantsAtrial fibrillationVitamin K antagonistmedicine.diseaseClinical trialStrokeRC666-701SurgeryCardiology and Cardiovascular MedicinebusinessIndian heart journal
researchProduct